Quinapril 20 mg twice daily for 4 weeks significantly lowered blood pressure by decreasing total peripheral resistance without producing tachycardia or increasing cardiac output compared with placebo.
RCT (n=10)
The hemodynamic effects of quinapril, a novel nonsulfhydryl-containing angiotensin-converting enzyme (ACE) inhibitor, were assessed in 10 patients with mild-to-moderate essential hypertension. Compared with placebo, quinapril (20 mg) administered twice daily for 4 weeks significantly lowered blood pressure by decreasing total peripheral resistance without producing tachycardia, an increase in cardiac output, or a rise in plasma catecholamines. Quinapril significantly reduced renal, but not forearm, vascular resistance. Renal blood flow, glomerular filtration rate, and filtration fraction remained unchanged. Left ventricular wall stress was markedly reduced by quinapril, but during the relatively short treatment period, only a nonsignificant trend toward reduction in left ventricular mass was observed. These findings suggest that quinapril is an effective antihypertensive agent that lowers peripheral resistance without increasing cardiac output or disturbing autoregulation of renal hemodynamics.
Gupta et al. (Sun,) conducted a rct in mild-to-moderate essential hypertension (n=10). quinapril vs. placebo was evaluated on blood pressure and total peripheral resistance. Quinapril 20 mg twice daily for 4 weeks significantly lowered blood pressure by decreasing total peripheral resistance without producing tachycardia or increasing cardiac output compared with placebo.